TDTalita Almeida Durães

Talita Almeida Durães

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Talita Almeida Durães has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the Adolescent Window: HPV Vaccination in Adult Women

    by Isadora Rodrigues Almeida, Marcela Fermoselle de Vita Silva, Thamy Cristina Campos, Talita Almeida Durães, Luana dos Santos Ribeiro, Manuela Cândido Amaral dos Reis, Gustavo Yano Callado, Antonio Braga, Edward Araujo Júnior, Gloria Calagna

    Human papillomavirus (HPV) vaccination has traditionally targeted girls and adolescents before sexual debut, when its preventive potential is greatest. However, many women reach adulthood unvaccinated or incompletely vaccinated, a gap widened by the COVID-19 pandemic. This narrative review summarizes the current evidence on HPV vaccination in adult women and its implications for gynecological practice. Sexual debut, previous infection, or a positive HPV test does not preclude benefit, because few women have been exposed to all vaccine types; nevertheless, the vaccine is prophylactic and does not treat established infection or lesions. In women aged 27 to 45 years, trials show favorable immunogenicity, efficacy, and safety, and vaccination is recommended through shared clinical decision-making that considers prior exposure and the risk of new exposures. Evidence above 45 years of age remains scarce. After excisional treatment of cervical intraepithelial neoplasia grade 2 or worse, meta-analyses predominantly based on observational studies suggest lower recurrence rates following adjuvant vaccination, although this benefit has not been consistently confirmed by randomized controlled trials. We also discuss additional vaccination with the nonavalent vaccine after bivalent or quadrivalent series, single-dose schedules, people living with HIV, and cervical screening in vaccinated women, in whom HPV-based testing maintains better performance than cytology. Missed opportunities remain common, and the absence of a recommendation from a health care professional is among the main reasons adults remain unvaccinated. Reviewing vaccination history at every gynecological visit, combined with individualized counseling, may help close the gap between vaccinated young cohorts and unvaccinated adult women and support cervical cancer elimination goals.

  • Open Access

    Maternal–Fetal Implications of Herpes Virus Infection: An Updated Review

    by Stefany Silva Pereira, Beatriz Bussi Rosolen, Talita Almeida Durães, Marcela Fermoselle de Vita Silva, Giovanna Alves de Britto, Camila Silva Belo, Thamy Cristina Campos, Gustavo Yano Callado, Susana Cristina Aidé Viviani Fialho, Antonio Braga, et al.

    Herpes simplex virus (HSV) infection is highly prevalent worldwide and poses important risks during pregnancy due to the potential for vertical transmission and severe neonatal disease. HSV-1 is traditionally associated with orofacial lesions and HSV-2 with genital infection; however, HSV-1 has emerged as a significant cause of genital and neonatal herpes. Physiological immunomodulation during pregnancy may facilitate viral reactivation and replication. Vertical transmission may occur intrauterinely, intrapartum, or postnatally, with approximately 85% of neonatal infections acquired during delivery through contact with infected genital secretions. The risk is highest when primary maternal infection occurs in the third trimester, before adequate transplacental transfer of protective antibodies. Neonatal infection may present as disease limited to the skin, eyes, and mouth; central nervous system involvement; or disseminated multiorgan disease, the latter associated with high morbidity and mortality. Maternal infection ranges from asymptomatic viral shedding to painful vesiculoulcerative lesions and, rarely, disseminated disease. Because asymptomatic shedding is common, diagnosis relies on laboratory confirmation using polymerase chain reaction (PCR) or viral culture, with type-specific serology aiding in distinguishing primary from recurrent infection. Management aims to reduce symptoms, viral shedding, recurrences near delivery, and vertical transmission. Acyclovir and valacyclovir are safe and effective in pregnancy. Suppressive therapy from 36 weeks’ gestation reduces recurrences and viral shedding at delivery and decreases the need for cesarean delivery, which is recommended when active lesions or prodromal symptoms are present at labor. Neonatal herpes requires prompt recognition and intravenous acyclovir therapy to reduce mortality and neurological sequelae. Preventive strategies include counseling, behavioral risk reduction, suppressive antiviral therapy, and avoidance of neonatal exposure to active lesions.

  • Open Access

    Maternal–Fetal Implications of Mpox Infection: Current Evidence

    by Stefany Silva Pereira, Antonio Braga, Beatriz Bussi Rosolen, Talita Almeida Durães, Marcela Fermoselle de Vita Silva, Giovanna Alves de Britto, Giuliana Augustinelli Sales, Gustavo Yano Callado, Camilla Martins dos Santos Maia, Evelyn Traina, et al.

    Mpox is an emerging zoonotic infection caused by the Monkeypox virus, an Orthopoxvirus with increasing global relevance following the 2022 multinational outbreak. Historically endemic to Central and West Africa, the disease has evolved from sporadic zoonotic transmission to sustained human-to-human spread, particularly through close physical and intimate contact. Clinical manifestations typically include fever, lymphadenopathy, and progressive mucocutaneous lesions, although severity varies according to viral clade, immune status, and comorbidities. The 2022 outbreak, predominantly associated with the Clade IIb variant, was characterized by milder disease, localized lesions, and reduced mortality compared with the more virulent Clade I variant. Despite this, severe outcomes remain possible, particularly in vulnerable groups such as children, pregnant individuals, immunocompromised patients, and persons with extensive dermatological disorders. Diagnosis relies primarily on polymerase chain reaction testing from lesion-derived samples, with genomic sequencing serving as a complementary tool for epidemiological surveillance. Management is largely supportive, though antivirals such as tecovirimat may be considered in severe cases or in high-risk populations. Data regarding therapeutic safety in pregnancy are limited; however, tecovirimat appears to have the most favorable profile, whereas cidofovir and brincidofovir remain contraindicated. Prevention strategies include targeted vaccination with the non-replicating Modified Vaccinia Ankara–Bavarian Nordic vaccine, used for both pre- and post-exposure prophylaxis, particularly in individuals at elevated risk. Given the evolving epidemiological profile, the potential for vertical transmission, and the risk of adverse perinatal outcomes, Mpox infection during pregnancy poses unique clinical challenges. This review synthesizes current evidence on virology, clinical presentation, diagnosis, prevention, and management, with an emphasis on obstetric considerations and public health implications.


  • Open Access

    Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential

    by Livian Cássia De Melo, Marina Macruz Rugna, Talita Almeida Durães, Stefany Silva Pereira, Gustavo Yano Callado, Pedro Pires, Evelyn Traina, Edward Araujo Júnior, Roberta Granese

    Congenital Rubella Syndrome (CRS) results from maternal infection with the rubella virus during pregnancy, particularly in the first trimester, when the risk of vertical transmission and severe fetal damage is highest. CRS is characterized by a broad spectrum of congenital anomalies, including sensorineural hearing loss, congenital heart defects, cataracts, neurodevelopmental delay, and behavioral disorders. Despite the absence of specific antiviral therapies, active immunization remains the only effective strategy to prevent rubella infection and its congenital consequences. Global immunization efforts, particularly in the Americas, have led to the elimination of rubella and CRS in several countries. However, challenges persist in the post-elimination era, including declining vaccine coverage, vaccine hesitancy, and setbacks caused by the COVID-19 pandemic. Diagnosis relies on maternal serology, fetal imaging, postnatal antibody testing, and molecular techniques. Management requires long-term, multidisciplinary follow-up due to the complex and lifelong sequelae affecting sensory, motor, and cognitive development. This review highlights the clinical, epidemiological, and pathophysiological aspects of CRS, while emphasizing the urgent need to maintain high vaccination coverage and strengthen surveillance systems. Sustained public health commitment is essential to prevent the reemergence of rubella and protect future generations from this preventable syndrome.